Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$2.33
$0.02(0.46%)
At close: 4:00 PM EST
$2.33
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$2.86 - $66.50
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$1.46M
Enterprise Value-$8.05M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$60.89K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1506000.00
Shares Outstanding648,314
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.09
Enterprise Value/Market Cap-5.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda0.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Equity BaseVery low debt and a meaningful rise in equity and assets improve financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, lowers interest burden, and gives management room to fund trials or pursue partnerships before commercial revenues materialize.
Registrational Phase 3 Program (eRapa) Anchors PipelineA registrational Phase 3 program represents a clearer path to approval compared with early-stage assets. This materially de-risks the portfolio on a program level, enhances partnering and licensing optionality, and can materially alter long-term cashflow prospects if successful.
Access To Non-dilutive Grants And Recent FinancingSecuring grant funding plus a $10M financing shows management can attract both non-dilutive and dilutive capital to sustain development. Grants reduce trial funding needs, extend runway, and demonstrate external validation useful for partnering and future capital raises.
Bears Say
Zero Revenue / Pre-commercial ProfileNo product revenue means the company will remain dependent on clinical success and external financing for the foreseeable future. That structural lack of operating cash inflows raises execution risk, elongates time-to-self-sufficiency, and increases potential shareholder dilution.
Persistent Negative Operating And Free Cash FlowContinued cash burn, despite improvement, shows the business has not reached cash generation. Ongoing negative FCF forces recurring capital raises or partnerships, which can delay programs if funding gaps emerge and increases dependency on capital markets or collaborators over the medium term.
Capital Structure Reorganizations And ADR Reverse SplitsLarge reverse splits and ADS ratio changes indicate low trading prices and a complex capital structure. These changes can reduce liquidity, complicate US investor access, signal compliance pressures, and may deter some institutional investors, impacting long-term shareholder composition.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $2.86 and its highest was $66.50 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $1.46M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2026 which is in 106 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 24, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 648,314 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
34.66% Other Institutional Investors
65.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---